On Friday, United Continental Holdings Inc (NYSE:UAL)’s shares declined -1.36% to $56.73.
United Airlines (UAL) declared that Gerald (Gerry) Laderman has been named acting chief financial officer. He succeeds John Rainey, who has resigned to become chief financial officer at PayPal Holdings, Inc.
Laderman, who has held legal and financial positions of increasing responsibility at the company for 27 years, will be responsible for the overall financial operations of the company, counting corporate finance, treasury, financial planning and analysis, tax, accounting, investor relations, fleet, procurement, internal audit and risk administration.
Laderman most has been senior vice president of finance, procurement and treasurer. While in this role, Laderman has done groundbreaking work in aircraft financing, counting leading the development of innovative debt structures, which have significantly lowered the cost of capital for the airline. Laderman has also led initiatives to maintain financial stability for the company during the turbulent times the airline industry has faced in the past.
United Continental Holdings, Inc., together with its auxiliaries, provides air transportation services in North America, the Asia-Pacific, Europe, the Middle East, Africa, and Latin America. It transports people and cargo through its mainline operations, which use jet aircraft with at least 118 seats, and its regional operations. A
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s shares dropped -11.41% to $106.19.
Alnylam Pharmaceuticals, Inc. ( ALNY), a leading RNAi therapeutics company, recently stated its merged financial results for the second quarter 2015, and highlighted recent progress in advancing its pipeline.
Second Quarter 2015 and Recent NoteworthyCorporate Highlights
- Advanced pipeline of investigational programs in Genetic Medicine Planned Therapeutic Area (STAr).
- Advanced RNAi therapeutic programs for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis).
- Continued enrollment in APOLLO Phase 3 study of patisiran in ATTR patients with Familial Amyloidotic Polyneuropathy (FAP).
- Advanced RNAi therapeutic programs for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis).
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The companys clinical development programs comprise Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 that is in Phase I clinical trial for hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia.
At the end of Friday’s trade, Banco Santander, S.A. (ADR) (NYSE:SAN)‘s shares dipped -0.29% to $6.76.
Santander Holdings USA, Inc. (SHUSA) is a wholly-owned partner of Banco Santander, S.A. (SAN). Santander Holdings USA, Inc. (SHUSA), parent company of Santander Bank, N.A., declared recently that its Board of Directors declared a dividend on SHUSA’s Preferred Stock. A dividend payment of $0.45625 per depositary share is payable on August 17, 2015 to holders of record on August 1, 2015 for SHUSA’s Series C Non-Cumulative Perpetual Preferred Stock (NYSE:SOVPRC).
Banco Santander, S.A. provides various banking products and services for individuals and companies. The company offers various deposit products, such as demand and time deposits; mortgages, auto finance, and personal credits; consumer finance; and mobile banking and electronic banking services. It is also engaged in corporate banking, treasury, and investment banking activities; designs and manages mutual and pension funds; invests in companies; and offers cash administration, trade finance and basic financing, and custody services.
Range Resources Corp. (NYSE:RRC), ended its Friday’s trading session with -5.88% loss, and closed at $35.72.
RANGE RESOURCES CORPORATION ( RRC) declared that it has redeemed all $500 million in outstanding principal of its 6.75% Senior Subordinated Notes due 2020 (CUSIP No. 75281AAL3) at a price of 103.375% of the unpaid principal amount plus accrued interest. The notes were redeemed on August 3, 2015 with borrowings under the Company’s bank credit facility.
Range had formerly funded the redemption at significantly lower cost through its offering in May 2015 of $750 million aggregate principal amount of senior notes due 2025 at par, which carry an interest rate of 4.875%. Pending redemption of the 6.75% senior subordinated notes, funds were used to temporarily reduce borrowings under the bank credit facility. With this transaction accomplished, Range has reduced its interest expense on the refinanced debt by 1.875%, which amounts to over $9 million annual savings, while extending the average maturity of its debt. Presently Range has a Moody’s corporate family rating of Ba1 with a positive outlook and a Standard & Poor’s corporate credit rating of BB+ with a stable outlook. Liquidity under the borrowing base of Range’s bank credit facility is about $2 billion after the redemption. The borrowing base is not planned for redetermination until May 1, 2016.
Range Resources Corporation, an independent natural gas, natural gas liquids (NGLs), and oil company, engages in the acquisition, exploration, and development of natural gas and oil properties in the United States. It holds interests in developed and undeveloped natural gas and oil leases in the Appalachian and Midcontinent regions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
